[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universiti Sains Malaysia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":589},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,43,72,99,128,157,179,201,224,252,278,306,333,358,382,403,424,443,463,491,515,544,565],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100617832","early-phase-1-long-term-effects-of-mobithron-advance-on-knee-osteoarthritis-aims-to-investigate-the-effects-of-mobithron-advance-on-oa-progression-100617832",false,"NCT07323745","Long-Term Effects of Mobithron Advance on Knee Osteoarthritis Aims to Investigate the Effects of Mobithron Advance on OA Progression","Long-Term Effects of Mobithron Advance on Knee Osteoarthritis","mobithron adv","Inclusion Criteria:\n\n* Males and female patients above 50 years old at the time of recruitment.\n* OA Diagnosis: Patients with one or both knee osteoarthritis according to clinical and radiological criteria of the American College of Rheumatology (ACR).\n* OA Grade: Kellgren Lawrence grade 1-3\n\nExclusion Criteria:\n\n* Secondary arthritis (e.g., rheumatoid arthritis, psoriatic arthritis).\n* History of joint surgery.\n* Patients who received steroid injection treatment within the last 3 months or hyaluronic acid injection treatment within the last 6 months.\n* Contraindications to Mobithron Advance (e.g., known allergies, severe liver or kidney disease).\n* Patients planning for knee surgery within the research period.\n* Patients on pharmacological treatment for osteoarthritis, other than rescue analgesic agent, e.g: glucosamine, chondroitin, oral steroid","ALL","50 Years",{"count":20,"type":21},84,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The goal of this clinical trial is to learn if the Mobithron Advance drug works to treat and slow the progression of osteoarthritis (OA) in patients. It will also learn about the safety and long-term effects of this drug. The main questions it aims to answer are:\n\n* Does long-term administration of Mobithron Advance can modify the progression of knee osteoarthritis with Kellgren-Lawrence grade 1 to 3 in HUSM patients?\n* Does long term usage of Mobithron Advance has safety profile? Researchers will compare the Mobithron Advance drug to a placebo (a look-alike substance that contains no drug) to see if said drug works to treat OA.\n\nParticipants will:\n\n* Undergo pre-study assessment (baseline assessments) during first visit\n* Take oral Mobithron Advance daily for 1 year\n* Visit the clinic once at 3 months, 6 months and 12 months intervals from the initial visit for follow up assessments",[27],"Osteoarthritis (OA) of the Knee",[29],"Mobithron Advance","RECRUITING","2026-06-09",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":34},"2026-05-03",{"date":38,"type":21},"2027-10-31",{"name":40,"class":41},"Universiti Sains Malaysia","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100638407","optimising-exercise-to-improve-physical-and-cognitive-frailty-in-mild-cognitive-impairment-100638407","NCT07600034","Optimising Exercise to Improve Physical and Cognitive Frailty in Mild Cognitive Impairment","Inclusion criteria:\n\n1. males and females aged 60 until 85\n2. living in the community,\n3. confirmed diagnosis of MCI\n4. able to walk without assistance for at least two minutes,\n5. able to participate in exercise intervention screened by a physician based on ACSM guidelines\n\nExclusion criteria:\n\n1. uncertain diagnosis of MCI,\n2. did not screen for ability to participate in exercise intervention,\n3. presence of other neurological, psychiatric, or cognitive impairment disorders,\n4. seriously ill, presence of Hepatitis B or C, cancer, and patients on immunosuppressant drugs,\n5. type 2 diabetes mellitus,\n6. uncontrolled hypertension or hypotension (systolic blood pressure \\>160 mm Hg and\u002For diastolic blood pressure \\>100 mm Hg at rest),\n7. unstable cardiac, renal, lung, liver, or other severe chronic disease,\n8. history of myocardial infarction and\u002For stroke within previous year,\n9. vision\u002Fhearing disorder,\n10. musculoskeletal disorders that affect physical function such as osteoporosis, severe knee osteoarthritis, and degenerative spinal condition,\n11. presence of any major psychiatric disorder (a clinical diagnosis of major depressive disorder, bipolar or schizophrenia)\n12. history of vitamin B12 deficiency or hypothyroidism (stable treatment for at least 3 months is allowed)\n13. serious or non-healing wound, ulcer, or bone fracture","60 Years","85 Years",{"count":52,"type":21},36,[54],"NA","This investigational research aims to understand the mechanism of delaying the progression of dementia through different types of exercise. Exercise plays a protective role by attenuating the progression of cognitive impairments in mild cognitive impairment (MCI), an early and reversible stage of dementia. However, how different types of exercise induce changes in physical frailty and cognitive function is understudied. The participants will be randomized to receive an exercise intervention program (cycling or strength training) for 12 weeks or a control group.\n\nThe participants will be asked to perform certain cognitive and physical assessments at the start of the study, at the end of 12 weeks of exercise intervention, and 4 weeks after the end of the intervention. Below is the list of the assessments:\n\n* Patient Health Questionnaire-9 (PHQ-9)\n* World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0-12)\n* Self-report on sociodemographic characteristics, ethnicity, socioeconomic status, educational level, smoking status, alcohol intake, comorbidities, chronic medications, social activities, history of falls\n* body height, weight and fat percentage, heart rate, blood pressure, Dual-Energy X-Ray Absorptiometry (DEXA) scan: measurements to evaluate overall physical characteristics\n* handgrip strength: to evaluate musculoskeletal function\n* Stroop test: to evaluate information processing speed and executive cognitive control\n* n-back task: to evaluate working memory and executive function\n* Timed Up and Go (TUG) test: to measure balance\n* single-task gait: to measure walking ability\n* double-task gait: to measure walking stability and attention\n\nDuring Stroop test, n-back task, Timed Up and Go (TUG) test, single-task gait and double-task gait, the participants will be equipped with a mobile functional near-infrared spectroscopy (fNIRS) device over their forehead. This device is used to detect changes in blood flow in the front area of the brain.\n\nTheir participation will last approximately 18 weeks (2 weeks of familiarization and assessment, 12 weeks of exercise intervention, and 4 weeks of follow-up).",[57],"Mild Cognitive Impairment (MCI)",[59,60,61,62],"Aerobic exercise","Strength training","fNIRs","Ageing","NOT_YET_RECRUITING","2026-05-17",{"date":66,"type":34},"2026-05-20",{"date":68,"type":21},"2026-07-01",{"date":70,"type":21},"2028-12-31",{"name":40,"class":41},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100618932","the-effects-of-eight-week-baduanjin-exercise-on-chronic-low-back-pain-and-disability-among-office-workers-100618932","NCT07338045","The Effects of Eight-Week Baduanjin Exercise on Chronic Low Back Pain and Disability Among Office Workers.","The Effects of Eight-Week Baduanjin Exercise on Chronic Low Back Pain and Disability Among Office Workers","Inclusion Criteria:\n\n\\-\n\nThis study specifically targets office workers diagnosed with mechanical (or non-specific) chronic low back pain, which refers to persistent low back pain without a specific identifiable pathological cause such as disc herniation, spinal stenosis, or inflammatory diseases. Mechanical low back pain is the most common form of chronic low back pain among sedentary populations, particularly office workers, and is primarily attributed to musculoskeletal imbalances, poor posture, and prolonged sitting.Participants were included in the study if they met the following criteria:\n\n1. Age and Occupational Requirements: Office workers between the ages of 20 and 55 years with at least two years of continuous employment.\n2. History of Chronic Low Back Pain: Presence of persistent or recurrent low back pain localized below the costal margin and above the inferior gluteal folds, with a duration of more than three months.\n3. Pain Intensity Assessment: A pain score exceeding 40 mm on a 100 mm Visual Analogue Scale (VAS), indicating a moderate level of pain.\n4. Clinical Diagnosis Confirmation: Participants must be diagnosed with mechanical (non-specific) chronic low back pain by orthopaedic sports medicine specialists from the First Affiliated Hospital of Xi'an Jiaotong University. All participants will be required to submit their annual full-body medical examination report provided by the university between May 30 and July 30 each year. The Principal Investigator will collect these reports in advance and arrange for orthopaedic sports medicine specialists from the affiliated hospital to conduct an on-site screening at Xi'an Jiaotong University City College. During this process, specialists will review participants' medical history, evaluate physical symptoms, and consider available imaging reports (e.g., X-rays or MRI scans if previously conducted) to confirm the absence of specific spinal pathologies such as disc herniation or spinal stenosis. These specialists are experts in diagnosing and managing musculoskeletal conditions related to physical activity and sports, ensuring accurate assessment and classification of participants' chronic low back pain. Their involvement guarantees both clinical validity and safety in participant selection.\n5. Cognitive and Physical Function: Normal cognitive function, adequate communication and interaction skills, and the physical ability to perform the basic movements of Baduanjin exercise. Participants must also have voluntarily provided written informed consent and agreed to comply with all study procedures throughout the research period.\n6. Employment Status: Staff members currently employed at Xi'an Jiaotong University City College. This criterion ensures that the study population consists exclusively of sedentary office workers within the university setting, enhancing homogeneity and relevance to the target demographic.\n\nExclusion Criteria:\n\n\\-\n\nSubjects are excluded from this study if they:\n\n1. Those with other spinal pathologies such as lumbar fractures, lumbar disc herniation, spondylolisthesis, intravertebral occupancy, lumbar spinal stenosis, and severe osteoporosis. These conditions may interfere with the interpretation of outcomes related to chronic low back pain of non-specific origin, and could also affect the safety or effectiveness of the Baduanjin exercise intervention.\n2. Persons with contraindications such as leukaemia, thrombocytopenia and other diseases with bleeding tendency, acute infectious diseases and oncological diseases. These systemic illnesses may affect participant safety or confound the results, and are therefore not included in the target population of office workers with chronic low back pain.\n3. Suffering from diseases of liver and kidney function, serious cardiac disorders, and other diseases affecting the study. The presence of these comorbidities could influence the ability of participants to safely complete the Baduanjin exercise program, and thus they are excluded to ensure homogeneity among the target group of individuals with chronic low back pain.\n4. Women who are pregnant. Pregnancy-related changes in posture and musculoskeletal loading can affect low back pain symptoms and response to exercise, which may confound the study findings.\n5. Subjects who do not agree to sign the informed consent form. All participants will be required to submit their annual full-body medical examination report provided by the university between May 30 and July 30 each year. The Principal Investigator will collect these reports in advance and arrange for orthopaedic sports medicine specialists from the affiliated hospital to conduct an on-site screening at Xi'an Jiaotong University City College. During this process, the specialists will review all relevant medical findings, including imaging results, laboratory tests, and physician notes, to identify any conditions that meet the exclusion criteria. Participants found to have spinal pathologies, systemic illnesses, or other comorbidities that may affect safety, intervention effectiveness, or study outcomes will be excluded from the study. These exclusion criteria are designed to ensure that the final sample consists exclusively of individuals with mechanical (non-specific) low back pain, thereby enhancing the homogeneity of the study population and minimizing confounding factors in evaluating the effects of Baduanjin exercise.","20 Years","55 Years",{"count":82,"type":21},30,[54],"Office workers often suffer from chronic low back pain due to long hours of sitting and poor posture. This study will test whether Baduanjin-a gentle, traditional Chinese exercise-can help reduce pain and improve physical function in office staff with long-standing back pain. Thirty participants will be randomly assigned to either practice Baduanjin for eight weeks or receive no special intervention. Researchers will measure changes in pain levels, movement ability, balance, posture, and daily functioning before and after the program. Baduanjin is a safe, low-cost, and easy-to-learn exercise that could be widely used in community health settings as a non-drug therapy for back pain.",[86,87],"Low Back Pain","Baduanjin",[89,90],"Office Workers","Non-pharmacological Intervention","2026-05-15",{"date":93,"type":34},"2026-05-19",{"date":95,"type":34},"2026-03-15",{"date":97,"type":21},"2026-07-31",{"name":40,"class":41},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":42},"100624493","development-of-a-self-assessment-tool-for-personalized-preventive-periodontal-care-among-the-saudi-population-using-semi-supervised-learning-100624493","NCT07410351","Development of A Self-Assessment Tool for Personalized Preventive Periodontal Care Among the Saudi Population Using Semi-Supervised Learning","Development and Validation of a Self-assessment Tool for Periodontal Disease Risk Assess Among the Saudi Population Using Semi-supervised Learning","Inclusion Criteria:\n\n* Adult aged 18 years or older\n* Able to read and understand the study information and provide informed consent\n* Able to complete the online questionnaire independently (on a smartphone\u002Ftablet\u002Fcomputer)\n* Willing to undergo a same-visit clinical periodontal examination\n* Has natural teeth present (dentate)\n\nExclusion Criteria:\n\n* Completely edentulous (no natural teeth)\n* Currently undergoing active periodontal treatment (e.g., scaling and root planing) or received periodontal therapy within the past \\[6 months\\]\n* Took systemic antibiotics within the past \\[3 months\\]\n* Unable to complete the questionnaire or examination due to cognitive impairment, severe illness, or communication barriers that prevent informed consent\n* Refuses or is unable to tolerate the periodontal clinical examination",true,"18 Years",{"count":109,"type":21},393,"OBSERVATIONAL","This observational study will collect labeled data to assess the accuracy of an online periodontal self-assessment tool in adults. Participants will complete the questionnaire and then undergo a clinical periodontal examination during the same visit. The study will compare questionnaire-based results with clinical examination results to evaluate diagnostic accuracy and agreement.",[113,114,115],"Periodontal Diseases","Periodontitis","Gingivitis",[117,118,119],"Periodontal diseases","risk assessment","self-report","2026-04-28",{"date":122,"type":34},"2026-05-05",{"date":124,"type":34},"2026-02-15",{"date":126,"type":21},"2026-10-15",{"name":40,"class":41},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100561358","efficacy-of-investigator-product-for-the-amelioration-of-digital-eye-strain-in-children-100561358","NCT06589128","Efficacy of Investigator Product for the Amelioration of Digital Eye Strain in Children","Efficacy of Investigator Product for the Amelioration of Digital Eye Strain in Children: a Randomized, Double-blind, Placebo-controlled Human Clinical Trial","DES","Inclusion Criteria:\n\n* Children with DES (CVS-Q score 6-18)\n\nExclusion Criteria:\n\n* Children with CVS-Q score ≥ 19\n* Children who wear contact lenses\n* Children with any diagnosed ocular motility disorder or accommodative\u002Fbinocular vision issues\n* Participants who are colour-blind\n* Participant on any retinols and carotenoid supplements\n* Participants who have immunosuppressive disorders or are taking immunosuppressive medication\n* Atopy, allergic disorders\n* Anaemia\n* Ophthalmic laser treatment (less than 3 months)\n* Systemic disease associated with dry eye\n* Blepharitis\n* Having liver (chronic liver failure, cirrhosis, all types of hepatitis), kidney (chronic kidney disease, haemodialysis) or haematological (anaemia, thalassemia, haemophilia) disorders\n* Psychiatric disease\u002Fmental retardation (bipolar disorder, depression, schizophrenia)\n* Cancer (all types), and endocrine disorders (Cushing's disease, gigantism and hyperthyroidism)\n* Use of steroids, chemotherapy or radiotherapy\n* Currently under another supplementary program","10 Years","11 Years",{"count":139,"type":21},70,[54],"Computer vision syndrome (CVS), also referred to as Digital eye strain (DES), is a group of eye and vision problems caused by prolonged use of electronic devices. The American Optometric Association (APA) defines DES as a group of eye and vision-related problems caused by prolonged computer, tablet, e-reader, and cell phone use. Currently, for more than 20 years, DES has been recognised as a public health issue, and the terms DES are also used to describe the condition, attributed to the wide range of digital devices associated with potential problems.",[143],"Digital Eye Strain (DES)",[145,146,147],"Children","Digital Eye Strain","Astaxanthin","2026-04-27",{"date":150,"type":34},"2026-04-29",{"date":152,"type":34},"2024-10-01",{"date":154,"type":21},"2026-06-30",{"name":40,"class":41},2,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":106,"sex":164,"minAge":107,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100634325","the-effectiveness-of-motivational-interviewing-in-preventing-early-childhood-caries-among-mothers-of-infants-in-terengganu-100634325","NCT07538219","The Effectiveness of Motivational Interviewing in Preventing Early Childhood Caries Among Mothers of Infants in Terengganu.","The Effectiveness of Motivational Interviewing in Preventing Early Childhood Caries: A Cluster Randomised Controlled Trial Among Mothers of Infants in Terengganu.","Inclusion Criteria:\n\n* Mothers:\n\n  * Malaysian citizens\n  * Can read and understand Bahasa Malaysia\n  * Aged 18 years old and above\n* Infants:\n\n  * Aged 6 months old (with or without erupted teeth)\n  * Born full-term (≥37 weeks of gestation)\n  * Without diagnosed congenital anomalies or syndromes\n\nExclusion Criteria:\n\n* Mothers\n\n  o Mothers experiencing postpartum depression or other significant postnatal issues\n* Infants\n\n  * Diagnosed with special needs, chronic diseases, or developmental defects\n  * Infants who are at risk for oral health problems due to pre-existing medical conditions\n  * Infants requiring specialized oral healthcare, such as those with cleft lip and palate, enamel hypoplasia","FEMALE",{"count":166,"type":21},228,[54],"This study will be conducted in Ministry of Health (MOH) Maternal and Child Health Clinics (MCHCs) and MOH dental clinics in Setiu and Hulu Terengganu, selected for their similar sociodemographic characteristics. A two-arm, parallel cluster-randomized controlled trial (1:1 allocation) will be implemented, where the study group receives Anticipatory Guidance (AG) through Motivational Interviewing (MI), and the control group receives conventional MOH AG.\n\nMothers aged ≥18 years who can understand Bahasa Malaysia and their healthy 6-month-old infants (full-term, without congenital conditions) are eligible. Mothers with postpartum depression and infants requiring special oral healthcare are excluded. A total of 228 mother-infant pairs will be recruited using multistage sampling. Three MCHCs from Setiu and three randomly selected MCHCs from Hulu Terengganu will participate. Systematic sampling will be applied within each clinic.\n\nData collection occurs at infant ages 6, 9, and 12 months during routine immunization visits. At each visit, infants undergo oral examination using ICDAS and a caries risk assessment. Mothers complete age-specific validated questionnaires on knowledge and practices. The study group receives two MI sessions (at 6 and 9 months) with follow-up phone calls, while the control group receives routine AG by MOH staff.\n\nThe MI protocol will be developed based on established MI frameworks and be validated through expert review, will be pretested among mothers and dental officers\u002Ftherapists in MOH MCHC and MOH dental clinic in Besut district. While fidelity assessment of MI sessions conducted will be done using MITI 4.2.1 guidelines. All MI sessions will be delivered by the trained principal investigator. Approximately 8 minutes are required for infant oral examination, 7 minutes for questionnaire completion, and 30 minutes for MI.\n\nData will be analysed using descriptive statistics, paired t-tests, independent t-tests, McNemar's test, and Chi-Square test with significance set at p \\\u003C 0.05.\n\nEthical approval was obtained from Jawatankuasa Etika Penyelidikan Manusia USM (JEPeM)\u002F Human Research Ethics Committee USM (HREC) and Medical Research and Ethics Committee (MREC) MOH. Participation is voluntary, with confidentiality ensured. No major risks are expected.",[170,171],"Healthy Women","Caries of Infancy","2026-04-12",{"date":174,"type":34},"2026-04-20",{"date":172,"type":21},{"date":177,"type":21},"2026-11-30",{"name":40,"class":41},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":42},"100627459","cognitive-frailty-gait-biomechanics-for-early-dementia-detection-100627459","NCT07448909","Cognitive-Frailty Gait Biomechanics for Early Dementia Detection","gait dementia","Inclusion Criteria:\n\n* Older adults aged 50 years and above\n* Able to ambulate independently without the use of walking aids\n* Must be able to understand instructions, communicate effectively\n* Free from any acute or unstable medical conditions at the time of assessment.\n\nHealthy older adults group:\n\n-No history or symptoms of cognitive impairments and have normal cognitive screening results.\n\nMild Cognitive Impairment (MCI) group:\n\n-Must fulfill established diagnostic criteria for MCI, showing measurable cognitive decline without significant functional impairment and without a diagnosis of dementia.\n\nExclusion Criteria:\n\n* Present with any diagnosed neurological disorder such as stroke or Parkinson's disease\n* History of psychiatric illness, including major depressive disorder.\n* Individuals with uncontrolled cardiovascular, metabolic, or endocrine conditions\n* Have significant visual, auditory, or musculoskeletal impairments that may influence gait performance\n* Currently taking medications known to affect cognitive or motor function\n* Unable to provide written informed consent",{"count":187,"type":21},60,"The purpose of this study is to better understand how physical characteristics, walking patterns, and a blood-based brain health marker differ between older adults with dementia and healthy older adults.\n\nDementia is often associated with changes in physical health and movement, but these changes are not fully understood. This study asks whether people with dementia show differences in body composition, walking ability, and levels of brain-derived neurotrophic factor (BDNF), a protein involved in brain function, compared with individuals without dementia.\n\nTo answer this question, participants will complete a single assessment session that includes basic physical measurements, an assessment of walking while moving at a comfortable pace, and a small blood sample collection. The information collected will be used to compare the two groups and explore possible relationships between physical function, walking patterns, and BDNF levels.",[57],[191,192],"Dementia","Physical function","2026-02-26",{"date":195,"type":34},"2026-03-04",{"date":197,"type":21},"2026-02-01",{"date":199,"type":21},"2029-12-31",{"name":40,"class":41},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":106,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100623474","validity-of-a-self-reported-questionnaire-for-periodontal-status-in-a-saudi-population-100623474","NCT07397104","Validity of a Self-reported Questionnaire for Periodontal Status in a Saudi Population","Validity of a Self-Reported Questionnaire for Periodontal Status in a Saudi Population: A Cross-Sectional Clinical Validation Study","Inclusion Criteria:\n\n* Age 18 years or older\n* Able to provide informed consent\n* Able to complete the self-reported periodontal questionnaire\n* Willing to undergo a same-visit clinical periodontal examination\n\nExclusion Criteria:\n\n* Less than ten teeth present\n* Any condition that makes periodontal probing unsafe, as judged by the clinician according to local policy\n* Unable to complete study procedures or provide informed consent",{"count":209,"type":21},291,"This observational study will evaluate the accuracy of a self-reported periodontal questionnaire in adults attending screening appointments in Abha, Saudi Arabia. Participants will complete the questionnaire and then undergo a same-visit clinical periodontal examination. The study will compare questionnaire-based results with clinical examination findings to assess diagnostic accuracy and agreement.",[113,114,115],[213,214,215],"Periodontal disease","Validity","self-reported","2026-02-07",{"date":218,"type":34},"2026-02-11",{"date":220,"type":21},"2026-04-01",{"date":222,"type":21},"2026-10-29",{"name":40,"class":41},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":250,"locationsCount":251},"100623423","phase-4-supplementary-kelulut-honey-therapy-in-juvenile-open-angle-glaucoma-effects-on-il-6-rnfl-and-dry-eye-100623423","NCT07396441","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye.","HONEY-JOAG","Inclusion Criteria:\n\nJOAG patients age 15 years old and above until 40 years old at the time of diagnosis Compliant to conventional treatment achieved target intraocular pressure\n\nExclusion Criteria:\n\nPatients with allergy to honey or honey-based products OCT signal less than 6\u002F10 Concurrent retinal diseases and other optic neuropathies Systemic neurodegenerative disease Systemic comorbidities such as diabetes mellitus and autoimmune diseases Patients on other honey-based products for the last 3 months Patient who consumes honey-based products during the study duration of 3 months (monitoring via honey-diary, return of the used sachet during the follow up visits) Patients on anti-oxidants, traditional medications or herbal products for the last 3 months Topical usage of steroids, systemic steroids and non-steroidal anti-inflammatory drugs.\n\nSepsis Compliance less than 75%.","15 Years","40 Years",{"count":187,"type":21},[236],"PHASE4","The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.",[239,240,241,242,243],"Juvenile Open Angle Glaucoma","Dry Eye Disease (DED)","Interleukin 6","Retinal Nerve Fiber Layer Thickness","HbA1c Level","2026-02-03",{"date":246,"type":34},"2026-02-09",{"date":248,"type":34},"2026-01-15",{"date":154,"type":21},{"name":40,"class":41},4,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":258,"minAge":107,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":277,"locationsCount":42},"100617154","the-effects-of-neuromuscular-training-on-knee-biomechanics-during-jump-landing-among-college-basketball-players-post-acl-reconstruction-and-rehabilitation-100617154","NCT07314931","The Effects of Neuromuscular Training on Knee Biomechanics During Jump-Landing Among College Basketball Players Post ACL Reconstruction and Rehabilitation","Inclusion Criteria:Male college basketball players\n\nAge 18-25 years\n\nHistory of anterior cruciate ligament (ACL) reconstruction surgery at least 12 months before enrollment\n\nCleared by physician for sports participation\n\nWilling to provide informed consent and comply with study procedures\n\nExclusion Criteria:Previous ACL injury on the contralateral knee\n\nOther major lower-limb injuries (e.g., meniscus, cartilage, fractures) in the past 12 months\n\nCurrent knee pain, swelling, or instability that prevents safe participation\n\nNeurological, cardiovascular, or systemic conditions that may affect training safety\n\nParticipation in another structured neuromuscular training program within the past 6 months","MALE","25 Years",{"count":82,"type":21},[54],"Basketball players often injure the anterior cruciate ligament (ACL), a key structure that stabilizes the knee. Even after surgery and standard rehabilitation, many athletes continue to have problems with knee stability, movement control, and performance during jumping and landing. These issues increase the risk of re-injury and can limit their ability to return to competition.\n\nNeuromuscular training (NMT) is a type of exercise program that focuses on improving balance, muscle coordination, and movement patterns. It uses activities such as jump-landing drills, balance tasks, agility exercises, and core training. Previous research shows that NMT can help athletes land more safely, reduce harmful knee movements, and improve sport performance. However, little is known about its long-term benefits in college basketball players who are more than one year post-ACL surgery.\n\nThis study aims to evaluate whether a 12-week NMT program, added to standard basketball training, can improve knee biomechanics, stability, and performance in college basketball players with a history of ACL reconstruction. Thirty participants will be randomly assigned to either an NMT group or a control group. Both groups will complete basketball training, but only the NMT group will receive the additional neuromuscular exercises.\n\nKnee movement will be measured using 3D motion capture and force plates, and performance will be tested through vertical jumps and other sport-specific tasks. The main outcomes will include knee angles during landing, ground reaction forces, dynamic stability, and jump height.\n\nThe expected outcome is that athletes who undergo NMT will demonstrate safer landing strategies, better knee control, and improved performance compared to those who only receive standard basketball training. These findings may help coaches and healthcare providers design safer, more effective rehabilitation programs for athletes after ACL surgery.",[264,265,266,267,268,269,270],"Anterior Cruciate Ligament Reconstruction Rehabilitation","Knee Injuries","Biomechanical Data","Athletic Performance","Physical Fitness","Neuromuscular Training","Basketball Players","2026-01-06",{"date":273,"type":34},"2026-01-07",{"date":275,"type":21},"2025-12-10",{"date":91,"type":21},{"name":40,"class":41},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":305},"100613630","efficacy-in-preventing-hypertrophic-scars-a-randomised-controlled-trial-comparing-chitosan-cream-silicone-gel--olive-oil-100613630","NCT07269093","Efficacy in Preventing Hypertrophic Scars: A Randomised Controlled Trial Comparing Chitosan Cream, Silicone Gel & Olive Oil","Inclusion Criteria:\n\n* Patients with traumatic or surgical wounds which have healed by primary intention within 14 days\n* Length of scar at least 3cm\n\nExclusion Criteria:\n\n* Patients with seafood allergy\n* Patients with scar from wounds that were complicated by infection or wound breakdown\n* Patients who have undergone scar treatment by other modalities\n* Patients with history of keloids \u002F hypertrophic scars\n* Pregnant patients","65 Years",{"count":286,"type":21},120,[54],"The goal of this clinical trial is to compare the efficacy of three different topical applications in preventing hypertrophic scars in adults with scars healed after suturing. The main question it aims to answer is: Is Chitosan cream effective in preventing hypertrophic scars?\n\nResearchers will compare Chitosan cream with silicone gel and olive oil to see if there is any difference in their efficacies.\n\nParticipants will be randomly assigned to three groups, with each group using a different topical application. They will be instructed to:\n\n* apply the topical application on their scar twice a day for 8 weeks\n* attend follow-up visits at 4, 12 and 24 weeks for a doctor to assess their scar and take clinical photographs\n* immediately inform the researcher if they experience any side effects",[290],"Hypertrophic Scars",[292,293,294,295,296],"Chitosan","silicone gel","olive oil","hypertrophic scars","prevention","2025-12-28",{"date":299,"type":34},"2026-01-02",{"date":301,"type":34},"2025-12-21",{"date":303,"type":21},"2026-11",{"name":40,"class":41},3,{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":259,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":42},"100616748","the-effects-of-magnesium-mg-supplement-and-alternate-maxillary-expansion-and-constriction-alt-ramec-in-patient-with-transverse-maxillary-deficiency-tmd-100616748","NCT07309640","The Effects of Magnesium (Mg) Supplement and Alternate Maxillary Expansion and Constriction (Alt-RAMEC) in Patient With Transverse Maxillary Deficiency (TMD)","The Effects of Magnesium (Mg) Supplement and Alternate Maxillary Expansion and Constriction (Alt-RAMEC) in Patient With Transverse Maxillary Deficiency (TMD): A Randomized Clinical Trial.","Mg + Alt-RAMEC","Inclusion Criteria:\n\n* Inclusion Criteria\n\n  1. All participants were young adults, from the 18- 25 age group (males or females).\n  2. There is a maxillary skeletal deficiency in every patient. (Anteroposterior deficiency, transverse bilateral\u002Funilateral deficiency)\n  3. All teeth erupted without any abnormalities in term of shape and size.\n  4. Good oral hygiene and non-smoking habits.\n\nExclusion Criteria:\n\n1. History of previous orthodontic treatment or maxillary expansion\n2. Patients with severe progressive periodontal disease\n3. Patients with severe craniomaxillofacial deformities such as cleft lip and palate\n4. Mid palatal fusion without successful expansion\n5. First molar absent or impacted in the patient.\n6. Patients who have bone loss, gingival recession, or persistent gingival inflammation.\n7. Individuals with a high gag reflex.\n8. History of a life-threatening medical condition, such as diabetes mellitus, or a chronic disease such as organ transplant rejection or cancer in patients receiving chemotherapy or radiation therapy and high risk of infections.",{"count":315,"type":21},38,[54],"This randomized clinical trial evaluates the effect of combining magnesium supplementation with an orthodontic technique called Alternate Maxillary Expansion and Constriction (Alt-RAMEC) using a Micro-implant Assisted Rapid Palatal Expansion (MARPE) appliance to treat adults (18-30 years) with transverse maxillary deficiency (TMD). TMD is a condition where the upper jaw is narrower than normal, which can affect bite and facial development.\n\nThe study involves two groups: one receiving the Alt-RAMEC protocol with MARPE alone, and the other receiving the same protocol alongside oral magnesium supplements. The effectiveness of these treatments will be compared by assessing changes in dental and skeletal structures through imaging techniques and evaluating muscle function. Participants will also report their pain and discomfort levels during the treatment.\n\nThis research aims to understand whether magnesium supplementation can enhance the effects of Alt-RAMEC treatment, improve patient outcomes, and reduce discomfort associated with orthodontic procedures.",[319,320],"Magnesium During Orthodontic Expansion","Orthodontic Patients Indicated for Maxillary Expansion",[322,323,324],"Expansion","Magnesium","Orthodontic","2025-12-19",{"date":327,"type":34},"2025-12-30",{"date":329,"type":21},"2026-01-01",{"date":331,"type":21},"2026-09-12",{"name":40,"class":41},{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":233,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":42},"100613596","proprioceptive-training-for-gait-and-knee-function-after-anterior-cruciate-ligament-reconstruction-100613596","NCT07268651","Proprioceptive Training for Gait and Knee Function After Anterior Cruciate Ligament Reconstruction","The Effect of Proprioceptive Training on Gait Performance and Knee Function in Patients With Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\n* Adults aged 18-40 years who have undergone primary unilateral anterior cruciate ligament reconstruction (ACLR) using an autograft.\n* At least 3 weeks postoperatively and currently engaged in the early-stage rehabilitation phase following ACLR.\n* Demonstrate near-full passive knee extension (≤ 5° loss) and at least 90° of passive knee flexion in the operated limb.\n* Able to walk independently without assistive devices and perform basic functional tasks (e.g., normal walking, single-leg stance).\n* No prior surgery or major injury to the contralateral knee or other lower limb joints.\n* No neurological, vestibular, or systemic conditions affecting proprioception, motor control, or physical performance.\n* Not currently participating in any structured proprioceptive or neuromuscular training programs.\n* Willing and able to comply with the intervention protocol and follow-up, and able to provide written informed consent.\n\nExclusion Criteria:\n\n* History of revision anterior cruciate ligament surgery, bilateral ACLR, or concurrent reconstruction of other knee ligaments (e.g., posterior cruciate ligament, medial collateral ligament, lateral collateral ligament) in the affected knee.\n* Meniscal repair or other intra-articular procedures that restrict knee range of motion beyond 3 weeks postoperatively.\n* Diagnosed osteoarthritis, rheumatoid arthritis, or other chronic joint diseases affecting the lower limbs.\n* Significant injury, surgery, or persistent pain in the contralateral knee, hip, ankle, or spine that could interfere with training or gait.\n* History or current diagnosis of neurological disorders (e.g., stroke, multiple sclerosis, Parkinson's disease) or vestibular dysfunction.\n* Any cardiopulmonary or systemic condition that contraindicates structured physical exercise.\n* Participation in other structured rehabilitation or proprioceptive training programs within the past 3 weeks.\n* Cognitive impairment or psychiatric conditions that may interfere with understanding instructions or complying with the protocol.",{"count":82,"type":21},[54],"Anterior cruciate ligament reconstruction (ACLR) is commonly performed to restore knee stability after injury, but many patients continue to experience gait abnormalities and reduced knee function during rehabilitation. Proprioceptive training is frequently included in rehabilitation programs to improve joint position sense, neuromuscular control, and movement coordination, yet its specific effects on gait performance and knee function after ACLR are not fully understood.\n\nThis study aims to investigate the effects of a 12-week proprioceptive training program on gait performance and knee function in patients who have undergone ACLR. Patients who meet the inclusion criteria will undergo baseline assessments, including gait analysis and knee function tests. They will then participate in a structured 12-week proprioceptive training program as part of their rehabilitation, followed by post-intervention assessments using the same measures.\n\nThe primary outcomes include changes in gait performance, such as walking speed, step length, cadence, support time, knee motion, and knee joint angles and moments during walking. Secondary outcomes include changes in knee function, including isokinetic muscle strength, joint position sense, and patient-reported outcomes measured by the Lysholm score and the International Knee Documentation Committee (IKDC) questionnaire. The findings from this study may help to clarify the functional benefits of proprioceptive training and support the development of more targeted and effective rehabilitation strategies for patients recovering from Anterior cruciate ligament (ACL) injuries.",[344],"Anterior Cruciate Ligament Reconstruction",[346,347,348,349],"Proprioceptive Training","Gait Performance","Knee Function","Joint Position Sense","2025-12-04",{"date":352,"type":34},"2025-12-08",{"date":354,"type":21},"2025-12",{"date":356,"type":21},"2026-04",{"name":40,"class":41},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":106,"sex":17,"minAge":107,"maxAge":284,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":156},"100606972","phase-2-the-effect-of-bifidobacterium-probiotics-on-gut-microbiota-changes-in-healthy-adults-during-short-term-travel-along-the-silk-road-100606972","NCT07182500","The Effect of Bifidobacterium Probiotics on Gut Microbiota Changes in Healthy Adults During Short-term Travel Along the Silk Road","Inclusion Criteria:\n\n* Generally healthy adults\n* Scheduled to undertake a short-term round trip (less than 7 days) to abroad\n* Able to complete study procedures\n* Willing to take intervention products\n\nExclusion Criteria:\n\n* Use of antibiotics, probiotics, hormones, immunosuppressants, biologics or JAK inhibitors within four weeks prior to study\n* Chronic or severe systemic diseases (including cardiovascular, hepatic, renal, malignant or psychiatric disorders)\n* Uncontrolled parasitic infections\n* Long-term use of corticosteroids, growth hormone, vitamin B12, lysine or inositol\n* Major surgery within one month\n* Allergy to probiotic components\n* Other conditions deemed inappropriate by investigators",{"count":365,"type":21},75,[367],"PHASE2","Journeying along the historic Silk Road exposes travelers to dramatic dietary shifts, unfamiliar microbial environments, and the physical stresses of long-distance travel-all known to disrupt gut health and cause gastrointestinal complaints, including traveler's diarrhea and sleep disturbances. Such disruptions may also elevate the risk of acquiring antibiotic-resistant organisms.\n\nThis randomized, double-blind, placebo-controlled trial evaluated whether probiotic supplementation can help maintain gut microbial balance and support traveler well-being during trips to Silk Road regions. In addition to monitoring changes in gut microbiota composition, the study assessed gastrointestinal symptoms, sleep quality, anxiety levels, overall well-being, gut immune markers, functional profiles of the microbiome, and the presence of antibiotic resistance genes.",[370],"Healthy Adult Volunteer",[372,373,374],"probiotc","travel","Silk Road","2025-12-02",{"date":275,"type":34},{"date":378,"type":34},"2025-10-16",{"date":380,"type":21},"2025-12-31",{"name":40,"class":41},{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":18,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":400,"leadSponsor":402,"locationsCount":42},"100614417","safety-and-efficacy-of-kelulut-honey-eyedrops-in-dry-eye-disease-100614417","NCT07279324","Safety and Efficacy of Kelulut Honey Eyedrops in Dry Eye Disease","Pilot Study on the Safety and Efficacy of Kelulut Honey Eyedrops for Dry Eye Disease","Inclusion Criteria:\n\n1. Age 18-50 years at the time of consent.\n2. Clinical diagnosis of dry eye disease in at least one eye, based on symptoms and clinical signs (Symptomatic dry eye, defined as an OSDI score ≥ 13; objective evidence of tear film instability, such as TBUT \\\u003C 10 seconds in at least one eye)\n3. Participants may be Treatment-naïve, OR on stable dry eye treatment for at least 2 weeks before enrollment.\n4. Willing to use Kelulut honey eyedrops three times daily for 1 month as instructed.\n5. Able and willing to attend all study visits (Baseline, Week 2, Week 4).\n\nExclusion Criteria:\n\n1. Known allergy or hypersensitivity to honey, bee products, or any component of the study formulations.\n2. Active ocular infection or inflammation (e.g., infectious conjunctivitis, keratitis, uveitis).\n3. Severe allergic conjunctivitis or other ocular surface diseases\n4. Significant meibomian gland dysfunction or blepharitis\n5. Ocular surgery or laser procedures within the past 6 months.\n6. Use of topical ocular medications other than lubricants within the past 30 days\n7. Contact lens wear within 1 week prior to baseline or expected during the study.\n8. Punctal plugs or other lacrimal procedures within the last 3 months.\n9. Systemic diseases that significantly affect the ocular surface and are unstable or uncontrolled (e.g., uncontrolled Sjögren's, uncontrolled rheumatoid arthritis, uncontrolled diabetes).\n10. Participation in another clinical trial or receipt of an investigational product within the past 30 days.\n11. Pregnant or breastfeeding women, or those planning pregnancy during the study.",{"count":390,"type":21},45,[54],"The goal of this clinical trial is to learn whether Kelulut honey eyedrops are safe and helpful in treating dry eye disease in adults. It will also learn about any side effects that may occur with the use of Kelulut honey eyedrops.\n\nThis Kelulut honey eyedrops are sterile ophthalmic solutions formulated with honey derived from stingless bees (Trigona spp.) at concentrations of 12.5% 25% and 50%. The eyedrop formulations are prepared according to a standardized laboratory protocol to ensure sterility, stability, and suitability for ocular use. Full formulation details are proprietary but can be provided to the ethics committee or regulatory authorities upon request.\n\nThe main questions this clinical trial aims to answer are:\n\n1. Does Kelulut honey improve tear film stability and dry eye symptoms?\n2. Are Kelulut honey eyedrops safe and well tolerated on the ocular surface?\n\nResearchers will compare different concentrations of Kelulut honey eyedrops to determine which concentration provides the best balance of safety and clinical benefit.\n\nParticipants will:\n\n1. Use Kelulut honey eyedrops (12.5%, 25%, or 50%) three times daily for 1 month, in addition to continuing their usual dry eye treatments.\n2. Attend scheduled follow-up visits (on week 2 and week 4) for eye examinations and dry eye assessments (e.g., TBUT, ocular surface staining, Schirmer test, and OSDI).\n3. Report any changes in symptoms or any discomfort, including stinging, redness, irritation, or other adverse effects experienced during the study.",[240,394,395],"Dry Eye Syndrome (DES)","Dry Eye Symptoms","2025-11-30",{"date":398,"type":34},"2025-12-12",{"date":220,"type":21},{"date":401,"type":21},"2026-10-30",{"name":40,"class":41},{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":233,"enrollmentInfo":410,"targetDuration":4,"studyType":22,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":42},"100613988","kelulut-honey-for-allergic-conjunctivitis-and-dry-eye-symptoms-100613988","NCT07273747","Kelulut Honey for Allergic Conjunctivitis and Dry Eye Symptoms","A Randomized Controlled Trial on the Effects of Oral Kelulut Honey Supplementation on Conjunctival Goblet Cell Density, Tear Film Stability, Dry Eye Disease Symptoms and Vision-Related Function in Patients With Allergic Conjunctivitis","Inclusion Criteria:\n\ni. Age between 18-40 years old ii. Confirmed diagnosis of allergic conjunctivits iii. Ocular surface disease index (OSDI) score \\> 12 iv. Compliance to conventional allergic conjunctivitis treatment\n\nExclusion Criteria:\n\ni. Any corneal or ocular surface pathology ii. Known diabetes mellitus or impaired glucose test iii. Ocular surface disease due to trachoma or other inflammatory conditions iv. Consume anti-inflammatory medications such as steroids, NSAIDS, oral doxycycline v. Concurrent use of other supplements or alternative therapies such as royal jelly, Manuka honey eye drop or omega-3 fatty acid vi. Using preservative-containing topical eye drops for ocular problems other than AC, such as anti-glaucoma medication vii. History of ocular trauma\u002Fsurgery or refractive surgery within last 3 years viii. Wearing contact lens in the last 3 months ix. Underlying inflammatory\u002F systemic disease and connective tissue diseases x. Recent conjunctivitis in the last 3 months xi. Patients on immunosuppressant",{"count":411,"type":21},72,[54],"The goal of this clinical trial is to learn if oral Kelulut honey works to improve eye symptoms in adults with allergic conjunctivitis. It will also look at how safe Kelulut honey is when taken as a daily supplement.\n\nThe main questions it aims to answer are:\n\n1. Does oral Kelulut honey reduce itchy, red, watery eyes and dry eye symptoms in people with allergic conjunctivitis?\n2. Does oral Kelulut honey improve tear film stability and the health of conjunctival goblet cells (special cells on the eye surface that help keep the eye moist)?\n3. What side effects or medical problems do participants have when taking Kelulut honey?\n\nResearchers will compare oral Kelulut honey to a honey-flavoured placebo syrup (a look-alike drink that does not contain Kelulut honey) to see if Kelulut honey is more effective than placebo for treating eye symptoms in allergic conjunctivitis.\n\nParticipants will:\n\n1. Take either oral Kelulut honey or a honey-flavoured placebo syrup every day for 1 month\n2. Continue their usual treatment for allergic conjunctivitis and dry eye disease as prescribed by their eye doctor\n3. Attend clinic visits for eye check-ups, including tests of tear film stability, dry eye symptoms, and eye surface health\n4. Answer questionnaires about their eye symptoms and how these affect their daily activities and vision-related quality of life\n\nParticipation is voluntary, and participants may stop taking part in the study at any time. Data collected up to the time they withdraw may still be used for research, but their routine medical care will not be affected",[395,415],"Allergic Conjunctivitis of Both Eyes","2025-11-28",{"date":418,"type":34},"2025-12-09",{"date":420,"type":34},"2025-09-17",{"date":422,"type":21},"2026-09",{"name":40,"class":41},{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":42},"100552943","phase-4-compare-the-efficacy-and-outcome-between-fentanyl-and-morphine-as-analgo-sedation-in-mechanically-ventilated-patients-100552943","NCT06479655","Compare the Efficacy and Outcome Between Fentanyl and Morphine as Analgo-sedation in Mechanically Ventilated Patients","Inclusion Criteria:\n\n* Age \\>18 years old\n* Patients who are expected by the ICU team to require invasive mechanical ventilation in ICU for at least more than 24 hours and for whom the ICU team decides to initiate continuous infusion of sedation\n* A patient who was ventilated and sedated not more than 12 hours before ICU admission.\n\nExclusion Criteria:\n\n* Patients with chronic use of narcotics\n* Patients with chronic liver failure or end-stage renal failure\n* Patients with severe chronic neurocognitive dysfunction\n* Patients with drug overdose\n* Patients with a known allergy to either morphine or fentanyl\n* Patients who are receiving neuromuscular blockers\n* Patients who are pregnant\n* Patients who are diagnosed to have severe traumatic brain in",{"count":431,"type":21},116,[236],"The primary aim of this clinical trial is to compare the effectiveness of fentanyl vs morphine as analgosedation in mechanically ventilated adult patients in the ICU. This study also aims to compare the outcomes of patients between the two groups.\n\nThe main questions it aims to answer are :\n\n1. Does propofol and fentanyl infusion as analgo-sedation achieve targeted sedation score at 12 and 24 hours compared to propofol and morphine infusion in mechanically ventilated adult patients in the intensive care unit (ICU)?\n2. Is there a difference between the proportion of patients requiring rescue sedation dose between the fentanyl and morphine groups?",[435],"Effect of Drug","2025-09-30",{"date":438,"type":34},"2025-10-06",{"date":440,"type":34},"2024-07-15",{"date":327,"type":21},{"name":40,"class":41},{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":106,"sex":17,"minAge":107,"maxAge":284,"enrollmentInfo":448,"targetDuration":4,"studyType":22,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":156},"100605538","phase-2-effect-of-probiotic-intervention-on-travel-related-health-conditions-during-short-term-overseas-travel-100605538","NCT07163819","Effect of Probiotic Intervention on Travel-Related Health Conditions During Short-Term Overseas Travel",{"count":449,"type":21},46,[367],"International travel disrupts gut health through dietary changes, microbial exposure, and stress, often causing gastrointestinal symptoms like traveler's diarrhea and sleep disturbances. These shifts may increase antibiotic resistance risks. Probiotics may help stabilize gut microbiota and improve well-being during travel. This randomized, double-blind, placebo-controlled trial investigated whether probiotic supplementation mitigates gut microbiota perturbations, gastrointestinal symptoms, and sleep issues in adults traveling abroad. The investigators also assessed changes in anxiety, well-being, gut immunity, microbial function, and antibiotic resistance genes.",[453],"Healthy Adults",[455,456],"probiotic","international travel","2025-09-10",{"date":420,"type":34},{"date":460,"type":34},"2025-07-31",{"date":380,"type":21},{"name":40,"class":41},{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":11,"sex":258,"minAge":470,"maxAge":49,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":473,"conditions":474,"keywords":476,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":42},"100601331","long-term-benefits-of-eccentric-cycling-exercise-in-patients-with-type-2-diabetes-mellitus-100601331","NCT07109102","Long-Term Benefits of Eccentric Cycling Exercise in Patients With Type 2 Diabetes Mellitus","Exploring Long-Term Benefits of Eccentric Cycling Exercise on Physiological Responses, Exercise Capacity, and Quality of Life in Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Male diagnosed with T2DM\n* Age 30 - 60 years old\n* Height ≥155cm (To ensure proper ergonomics, comfort and safety during cycling)\n* HbA1C level between 6-8%\n* No resistance exercise for ≤ 3 months before participating in the current study.\n* Physical inactivity (moderate to vigorous exercise ≤60 minutes weekly based on International Physical Activity Questionnaires-Short Form (IPAQ-SF))\n\nExclusion Criteria:\n\n* Acute illness or any foot ulcer, diabetic ulcer, retinopathy, kidney, musculoskeletal, cardiovascular, or neurological disorder that could impair exercise performance or pose a risk to participants during exercise.\n* Insulin injection","30 Years",{"count":82,"type":21},[54],"The goal of this interventional study is to evaluate the long-term benefits of eccentric (ECC) cycling exercise on physiological responses, exercise capacity, and quality of life (QoL) in patients with type 2 diabetes mellitus (T2DM). The main questions it aims to answer are:\n\n* What are the effects of ECC cycling compared to concentric (CON) cycling on physiological responses, exercise capacity, and QoL in patients with T2DM?\n* What are the differential effects of moderate- and high-intensity ECC cycling compared to CON cycling on physiological responses, exercise capacity, and QoL in patients with T2DM?\n\nResearchers will compare moderate- and high-intensity ECC cycling to CON cycling (conventional cycling) to see if ECC cycling can be a viable alternative or complement to existing exercise protocols for managing T2DM.\n\nParticipants will:\n\n* Undergo pre-, mid-, and post-intervention assessment\n* Perform either moderate- or high-intensity ECC cycling or moderate intensity CON cycling according to group randomisation by the researcher.\n* Start with two familiarisation sessions prior to the actual cycling training.\n* Perform cycling exercise twice per week for 10 weeks.",[475],"Type 2 Diabetes Mellitus (T2DM)",[477,478,479,480,481,482],"Eccentric cycling","eccentric exercise","exercise capacity","quality of life","physiological responses","Type 2 diabetes mellitus","2025-07-30",{"date":485,"type":34},"2025-08-07",{"date":487,"type":21},"2025-08",{"date":489,"type":21},"2026-08",{"name":40,"class":41},{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":499,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":514,"locationsCount":42},"100565812","evaluate-the-effect-of-synbiotics-in-irritable-bowel-syndrome-100565812","NCT06647043","Evaluate the Effect of Synbiotics in Irritable Bowel Syndrome","A Single-arm, Open-label Clinical Trial to Evaluate the Effect of SMT04 Pro in Irritable Bowel Syndrome (IBS)","IBSXtra02","Inclusion Criteria:\n\n* The subject must meet all of the inclusion criteria to participate in this study.\n\n  * Male or female,\n  * Aged from 18 to 70 years old\n  * Meet the criteria of the Rome-III-definition of IBS with diarrhoea or mixed subtypes, or functional diarrhoea: Rome-III-definition: Abdominal pain or abdominal discomfort on minimum of three days per month during the last three months, starting at least six months ago, and a minimum of two of the following criteria:\n\n    * Improvement of symptoms after defecation\n    * Start of symptoms in association with a change in stool frequency\n    * Start of symptoms in association with a change in stool consistency Subtype of IBS-D which requires more than 25% of your stools to be loose and less than 25% hard and lumpy; Subtype of IBS-M which your stools must be both hard and lumpy, as well as loose in consistency at least 25% of the time. Functional diarrhoea: The experience of loose or watery stools without pain occurring in at least 75% of bowel movements for at least three months over the last six months.\n  * Have the latest negative colonoscopy result within five years\n  * Literate and can complete questionnaire\n  * Written informed consent is obtained\n\nExclusion Criteria:\n\n* • Known inflammatory bowel disease, lactose intolerance or other malabsorption syndromes, celiac disease, diabetes mellitus, thyroid disfunction, cancer, immunodeficiency, autoimmune diseases, severe hepatic or renal insufficiency, other explainable causes of abdominal pain, diarrhoea or constipation\n\n  * Known operations involving small intestines and large intestines; or history of appendectomy, hysterectomy, and cholecystectomy in last 6 months\n  * Known severe mental illnesses; unstable type or dose of psychiatric drugs within the last 3 months that will affect their judgement of study participation\n  * Evidence of active infection at the time of inclusion\n  * History of use of prebiotics, probiotics, antibiotic therapy or anti-inflammatory drugs within the last 2 weeks\n  * Known current pregnancy or breast-feeding female","70 Years",{"count":501,"type":21},20,[54],"Irritable Bowel Syndrome (IBS) is a brain-gut-disorder characterized by a chronic relapsing-remitting nature of symptoms, including abdominal pain and altered bowel habits. Symptoms most likely result from complex interactions between several biological, psychological and social factors.\n\nProbiotic supplements are thought to improve IBS symptoms through manipulation of the gut microbiota. Some studies have suggested that different strains of probiotics may improve abdominal pain and reduce visceral hypersensitivity by modulation of expression of neurotransmitters and receptors involved in the modulation of pain, such as the opioid receptor or the cannabinoid receptor. In addition, probiotics have been shown to reduce intestinal cytokine secretion and improve epithelial barrier function in a mice model of intestinal inflammation.\n\nBifidobacteria and Streptococci strains had previously demonstrated efficacy in achieving symptom improvement in IBS patients. Thus, there is potential for SMT04, a health supplement, to be an option for IBS patients.",[505],"Irritable Bowel Syndrome (IBS)",[505,507],"Synbiotics","2025-04-06",{"date":510,"type":34},"2025-04-09",{"date":512,"type":34},"2025-02-23",{"date":436,"type":21},{"name":40,"class":41},{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":106,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":22,"phases":524,"briefSummary":525,"conditions":526,"keywords":530,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":42},"100576654","effect-of-aerobic-exercise-with-synchronous-music-on-functions-among-medical-students-100576654","NCT06788106","Effect of Aerobic Exercise With Synchronous Music on Functions Among Medical Students","Effect of Different Aerobic Exercise Intensities With Synchronous Music on Psychophysiological, Attentional, Executive Functions and Brain Functional Connectivity Among Medical Students in Jiangsu Province, China","Inclusion Criteria:\n\n* Medical students willing to participate in aerobic training\n* Population of low questionnaire evaluation results\n* Subjects achieved a result of 7met or more on the Treadmill Test using the Bruce protocol\n* The medical students with low to moderate physical activity level. They are able to exercise, once or twice per week, but are not in the habit of doing so daily\n\nExclusion Criteria:\n\n* History of major depressive disorder in the past 6 months\n* Have a history of alcohol, drug abuse or use of psychiatric drugs\n* Have a history of head trauma, neurological disease or other serious illness",{"count":523,"type":21},134,[54],"Researchers invite participants to volunteer to participate in this cross-sectional, interventional study. This research examines the effects of 8-week aerobic exercise of different intensities combining synchronized music on psychology, attention, and executive function among Chinese college students, and also validates the reliability and validity of the Chinese version of Brief College Student Hassles Scale, the Perceived Stress Scale for Medical Students, Brief Multidimensional Students'Life Satisfaction Scale, Positive Thinking Skills Scale, Attentional Function Index, Procrastination Assessment Scale-Student and Behavioral Assessment of the Dysexecutive Syndrome-College version, providing a research basis for aerobic exercise to improve the cognitive function and mental health level of Chinese college students. Participants will be invited to participate in the intervention study, in which participants will be assigned to the intervention group and control group. Participation in this study will last approximately 8 weeks for a total of 24 sessions, 40 minutes each session, and participants will not be forced to participate in this study if they do not wish to. This study will include up to 134 participants who will be assigned to the intervention and control groups in a randomized manner.",[527,528,529],"Psychological Stress","Aerobic Exercise","Medical Students",[531,532,533,534,535,536],"medical students","mental health","psychophysiological function","attentional function","executive funcion","brain functional connectivity","2025-03-24",{"date":539,"type":34},"2025-03-26",{"date":541,"type":34},"2025-02-26",{"date":301,"type":21},{"name":40,"class":41},{"id":545,"slug":546,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":22,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":42},"100559749","phase-2-the-effect-of-alpha-lipoid-acid-and-vitamin-b-preparation-on-diabetic-polyneuropathy-in-type-2-diabetes-mellitus-patient-100559749","NCT06568185","The Effect of Alpha Lipoid Acid and Vitamin B Preparation on Diabetic Polyneuropathy in Type 2 Diabetes Mellitus Patient","The Effectiveness of Fixed Dose Combination of Alpha Lipoic Acid and Vitamin B Preparations for Treatment of Diabetic Polyneuropathy in Type 2 Diabetes Mellitus Patients: A Randomized Placebo-controlled Trial","Inclusion Criteria:\n\n1. Aged 18 years and over\n2. Diagnosed with type 2 diabetes mellitus based on WHO diagnostic criteria for diabetes (Organization, 2020).\n3. Diagnose with diabetic polyneuropathy by Neurological Symptom Score (NSS) and Neuropathy Disability Score (NDS).\n\nExclusion Criteria:\n\n1. Those with a documented mental impairment which impacted on their ability to answer questions independently.\n2. People with peripheral vascular disease (non-palpable foot pulses, intermittent claudication)\n3. People with an amputated foot or leg\n4. Abnormal liver enzyme.\n5. People with renal impairment.\n6. People using drugs with possible influence on the study results (antidepressants, anticonvulsants, opiates, neuroleptics, antioxidants, and particularly methylcobalamin, pyridoxine and other B complex preparations)\n7. Pregnancy, lactation, or childbearing age without safe contraception\n8. History of allergy with vitamin B complex preparations (i.e. Vitamin B12, B6 and B1) and alpha lipoic acid.",{"count":552,"type":21},76,[367],"To evaluate the efficacy of combination of vitamin B and alpha lipoic acid formulations for the treatment of diabetic polyneuropathy in individuals with type 2 diabetes mellitus.\n\nMethodology :\n\nThis is a single-center, randomized, double-blind, placebo-controlled trial study.\n\nStudy duration May 2024 - September 2025\n\nStudy location :\n\nThis study will be conducted at the Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia.\n\nSource Reference :\n\nPeople with type 2 diabetes mellitus attending the Hospital Universiti Sains Malaysia.\n\nStudy source population :\n\nPeople with type 2 diabetes mellitus attended Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia during the study period.",[556],"Diabetic Polyneuropathy","2024-08-20",{"date":559,"type":34},"2024-08-23",{"date":561,"type":34},"2024-05-27",{"date":563,"type":21},"2025-09-01",{"name":40,"class":41},{"id":566,"slug":567,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":17,"minAge":573,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":575,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":4},"100546855","impact-of-surgical-site-infection-in-peritonitis-after-peritoneal-lavage-with-super-oxidixed-solution-100546855","NCT06400394","Impact of Surgical Site Infection in Peritonitis After Peritoneal Lavage With Super-oxidixed Solution","Impact of Surgical Site Infection in Peritonitis After Peritoneal Lavage With Super-oxidixed Solution: A Randomised Double-Blind, Placebo-controlled Trial","Plasso 2","Inclusion Criteria:\n\n1. Patients age 13yrs and above\n2. Diagnosed with perforated viscus intraoperatively\n3. Undergo Midline Laparotomy\n4. ASA 3 and below\n\nExclusion Criteria:\n\n1. Surgical technique: Laparoscopic washouts\n2. Patients on steroid treatment and immunosuppressant therapy.\n3. More than ASA 3\n4. Inability to give\u002Funderstand informed consent\n5. Revision-surgery (previous abdominal surgery within the last 30 days)\n6. Planned re-laparotomy within 30 days\n7. Terminal kidney failure requiring dialysis\n8. Concurrent abdominal wall infections","13 Years",{"count":431,"type":21},[54],"This is randomised double blinded placebo-controlled parallel-group study. Patients in Hospital Queen Elizabeth, Sabah and Hospital Universiti Sains Malaysia, Kelantan who undergo laparotomy for peritonitis will be equally randomised into two groups : intervention group receiving super-oxidised solution and the control group receiving normal saline during peritoneal and wound lavage.\n\nThis is a superiority study assessing the effectiveness of the intervention. The patient and doctors directly involved in the partient care will be blinded in this study",[578],"Surgical Site Infection",[580],"\"Peritonitis\" \"Peritoneal lavage\" \"surgical site infection\" \"super-oxidised solution\"","2024-08-01",{"date":583,"type":34},"2024-08-06",{"date":585,"type":21},"2024-09-01",{"date":587,"type":21},"2026-05-01",{"name":40,"class":41},""]